EUS-guided versus percutaneous liver biopsy: A prospective randomized clinical trial.

Autor:	Ali AH; Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA., Nallapeta NS; Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA.; Division of Gastroenterology, Hepatology, and Nutrition, University of Buffalo, Buffalo, NY, USA., Yousaf MN; Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA., Petroski GF; Biostatistics and Research Design Unit, School of Medicine, University of Missouri, Columbia, MO, USA., Sharma N; Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA., Rao DS; Department of Pathology and Anatomical Sciences, University of Missouri, Columbia, MO, USA., Yin F; Department of Pathology and Anatomical Sciences, University of Missouri, Columbia, MO, USA., Davis RM; Department of Radiology, Vascular and Interventional Radiology, University of Missouri, Columbia, MO, USA., Bhat A; Department of Radiology, Vascular and Interventional Radiology, University of Missouri, Columbia, MO, USA., Swi AIA; Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA., Al-Juboori A; Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA., Ibdah JA; Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA.; Research Service, Harry S. Truman Memorial Veterans Medical Center, Columbia, MO, USA.; Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO, USA., Hammoud GM; Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA.
Jazyk:	angličtina
Zdroj:	Endoscopic ultrasound [Endosc Ultrasound] 2023 May-Jun; Vol. 12 (3), pp. 334-341. Date of Electronic Publication: 2023 Jul 25.
DOI:	10.1097/eus.0000000000000010
Abstrakt:	Background and Objectives: Prospective studies comparing EUS-guided liver biopsy (EUS-LB) to percutaneous LB (PC-LB) are scarce. We compared the efficacy and safety of EUS-LB with those of PC-LB in a prospective randomized clinical trial. Methods: Between 2020 and 2021, patients were enrolled and randomized (1:1 ratio). The primary outcome was defined as the proportion of patients with ≥11 complete portal tracts (CPTs). The sample size (n = 80) was calculated based on the assumption that 60% of those in the EUS-LB and 90% of those in the PC-LB group will have LB with ≥11 CPTs. The secondary outcomes included proportion of patients in whom a diagnosis was established, number of CPTs, pain severity (Numeric Rating Scale-Pain Intensity), duration of hospital stay, and adverse events. Results: Eighty patients were enrolled (median age, 53 years); 67.5% were female. Sixty percent of those in the EUS-LB and 75.0% of those in the PC-LB group met the primary outcome ( P = 0.232). The median number of CPTs was higher in the PC-LB (17 vs 13; P = 0.031). The proportion of patients in whom a diagnosis was established was similar between the groups (92.5% [EUS-LB] vs 95.0% [PC-LB]; P = 1.0). Patients in the EUS-LB group had less pain severity (median Numeric Rating Scale-Pain Intensity, 2.0 vs 3.0; P = 0.003) and shorter hospital stay (2.0 vs 4.0 hours; P < 0.0001) compared with the PC-LB group. No patient experienced a serious adverse event. Conclusions: EUS-guided liver biopsy was safe, effective, better tolerated, and associated with a shorter hospital stay. Competing Interests: All authors have no conflict of interest to declare. (Copyright © 2023 The Author(s). Published by Wolters Kluwer on behalf of Scholar Media Publishing.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu